Safety and immunogenicity of different formulations of monovalent Influenza A/Astrakhan/3212/2020 like (H5N8) virus vaccine with AS03 adjuvant system in medically stable adults

Trial Identifier: 219833
Sponsor: GlaxoSmithKline
Start Date: August 2023
Primary Completion Date: May 2024
Study Completion Date: September 2024
Condition: Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, AL Anniston, AL, United States, 36207
United States, AL Mobile, AL, United States, 36608
United States, AZ Tempe, AZ, United States, 85281
United States, CA Chula Vista, CA, United States, 91911
United States, CA Long Beach, CA, United States, 90806
United States, CA Santa Ana, CA, United States, 92705
United States, FL Pembroke Pines, FL, United States, 33025
United States, GA Chamblee, GA, United States, 30341
United States, ID Meridian, ID, United States, 83642
United States, KS El Dorado, KS, United States, 67042
United States, KS Lenexa, KS, United States, 66219
United States, KY Lexington, KY, United States, 40509
United States, LA Metairie, LA, United States, 70006
United States, SC Anderson, SC, United States, 29621
United States, TN Knoxville, TN, United States, 37920
United States, TX Austin, TX, United States, 78745
United States, TX Boerne, TX, United States, 78006
United States, TX San Antonio, TX, United States, 78244
United States, TX Tomball, TX, United States, 77375
United States, VA Norfolk, VA, United States, 23507